The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Extrathyroidal manifestations of Graves’ disease: a 2014 update
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552
Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy
Mourits, M. P., Prummel, M. F., Wiersinga, W. M., & Koornneef, L. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2331047.x · Cited by 1,001
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
Bartalena, L., Baldeschi, L., Dickinson, A., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0666 · Cited by 795
Self-citationRelation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715
Self-citationManagement of Graves’ Ophthalmopathy: Reality and Perspectives*
Bartalena, L., Pinchera, A., & Marcocci, C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0393 · Cited by 677
Self-citationSelenium and the Course of Mild Graves' Orbitopathy
Marcocci, C., Kahaly, G. J., Krassas, G. E., Bartalena, L., Prummel, M., Stahl, M., Altea, M. A., Nardi, M., Pitz, S., Boboridis, K., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012985 · Cited by 619
Self-citationClinical Features of Graves' Ophthalmopathy in an Incidence Cohort
BARTLEY, G. B., FATOURECHI, V., KADRMAS, E. F., JACOBSEN, S. J., ILSTRUP, D. M., GARRITY, J. A., & GORMAN, C. A. (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70276-4 · Cited by 459
Self-citationLaurberg, P., Wallin, G., Tallstedt, L., Abraham-Nordling, M., Lundell, G., & Tørring, O. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0450 · Cited by 428
Intravenous Glucocorticoids for Graves' Orbitopathy: Efficacy and Morbidity
Zang, S., Ponto, K. A., & Kahaly, G. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1962 · Cited by 379
Bartalena, L., Krassas, G. E., Wiersinga, W., Marcocci, C., Salvi, M., Daumerie, C., Bournaud, C., Stahl, M., Sassi, L., Veronesi, G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2389 · Cited by 370
Self-citationPrednisone and Cyclosporine in the Treatment of Severe Graves' Ophthalmopathy
Prummel, M. F., Mourits, M. P., Berghout, A., Krenning, E. P., van der Gaag, R., Koornneef, L., & Wiersinga, W. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212002 · Cited by 359
Bartalena, L., & Tanda, M. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0806317 · Cited by 336
Self-citationTanda, M. L., Piantanida, E., Liparulo, L., Veronesi, G., Lai, A., Sassi, L., Pariani, N., Gallo, D., Azzolini, C., Ferrario, M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3873 · Cited by 328
Self-citation_, _., Wiersinga, W. M., Perros, P., Kahaly, G. J., Mourits, M. P., Baldeschi, L., Boboridis, K., Boschi, A., Dickinson, A. J., Kendall-Taylor, P., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02230 · Cited by 302
Diagnosis and management of Graves disease: a global overview
Bartalena, L. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.193 · Cited by 296
Self-citationEffect of Abnormal Thyroid Function on the Severity of Graves' Ophthalmopathy
Prummel, M. F. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00390170124027 · Cited by 238
VISA Classification for Graves Orbitopathy
Dolman, P. J., & Rootman, J. (2006) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/01.iop.0000235499.34867.85 · Cited by 234
Pfeilschifter, J., & Ziegler, R. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.8220832.x · Cited by 227 · cited 1×
“Accordingly, patients should be firmly encouraged to refrain from smoking, because quitting smoking has been associated with a decreased risk of developing exophthalmos and extraocular muscle dysfunction [25].”
Risk Factors for Development or Deterioration of Graves' Ophthalmopathy
Stan, M. N., & Bahn, R. S. (2010) · Thyroid · doi:10.1089/thy.2010.1634 · Cited by 227
Pretibial Myxedema: Pathophysiology and Treatment Options
Fatourechi, V. (2005) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200506050-00003 · Cited by 208
Self-citationThe Incidence of Graves' Ophthalmopathy in Olmsted County, Minnesota
BARTLEY, G. B., FATOURECHI, V., KADRMAS, E. F., JACOBSEN, S. J., ILSTRUP, D. M., GARRITY, J. A., & GORMAN, C. A. (1995) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)72666-2 · Cited by 198
Self-citationTreatment of Active Corticosteroid-Resistant Graves’ Orbitopathy
Pérez-Moreiras, J. V., Álvarez-López, A., & Gómez, E. C. (2014) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/iop.0000000000000037 · Cited by 198
Smoking and Thyroid-Associated Ophthalmopathy: A Novel Explanation of the Biological Link
Cawood, T. J., Moriarty, P., O’Farrelly, C., & O’Shea, D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1824 · Cited by 198
The effect of etanercept on Graves' ophthalmopathy: a pilot study
Paridaens, D., van den Bosch, W. A., van der Loos, T. L., Krenning, E. P., & van Hagen, P. M. (2005) · Eye · doi:10.1038/sj.eye.6701768 · Cited by 193
Psychosocial morbidity of Graves’ orbitopathy
Kahaly, G. J., Petrak, F., Hardt, J., Pitz, S., & Egle, U. T. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02352.x · Cited by 184
Dermopathy of Graves' Disease (Pretibial Myxedema): Long-Term Outcome
Schwartz, K. M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.438 · Cited by 176
Immunopathogenesis of Graves’ ophthalmopathy: The role of the TSH receptor
Iyer, S. R., & Bahn, R. S. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.10.003 · Cited by 155
Nyström, H. F., Jansson, S. K. G., & Berg, G. E. B. (2013) · Clinical Endocrinology · doi:10.1111/cen.12060 · Cited by 153
Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy
Smith, T. J., Hegedűs, L. D., & Douglas, R. S. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.10.002 · Cited by 152
Wiersinga, W. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0307 · Cited by 138
Moli, R. L., Baldeschi, L., Saeed, P., Regensburg, N. I., Mourits, M. P., & Wiersinga, W. M. (2007) · Thyroid · doi:10.1089/thy.2006.0267 · Cited by 136
Moshkelgosha, S., So, P., Deasy, N., Díaz‐Cano, S. J., & Banga, J. P. (2013) · Endocrinology · doi:10.1210/en.2013-1576 · Cited by 134
Menconi, F., Marinò, M., Pinchera, A., Rocchi, R., Mazzi, B., Nardi, M., Bartalena, L., & Marcocci, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1800 · Cited by 132
Self-citationThyroid Acropachy: Report of 40 Patients Treated at a Single Institution in a 26-Year Period
Fatourechi, V., Ahmed, D. D. F., & Schwartz, K. M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020746 · Cited by 129
Self-citationRapoport, B., Alsabeh, R., Aftergood, D., & McLachlan, S. M. (2000) · Thyroid · doi:10.1089/10507250050137761 · Cited by 129
Lai, A., Sassi, L., Compri, E., Marino, F., Sivelli, P., Piantanida, E., Tanda, M. L., & Bartalena, L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2130 · Cited by 129
Self-citationQuality of life in thyroid eye disease: impact of quality of care
Estcourt, S., Quinn, A. G., & Vaidya, B. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0055 · Cited by 124
Thyroid dermopathy and acropachy
Fatourechi, V. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.10.001 · Cited by 123
Self-citationPrevalence and natural history of Graves' orbitopathy in the XXI century.
Piantanida, E., Tanda, M. L., Lai, A., Sassi, L., & Bartalena, L. (2013) · PubMed · doi:10.3275/8937 · Cited by 122
Self-citationEnvironmental tobacco smoke exposure and eye disease
Lois, N., Abdelkader, E., Reglitz, K., Garden, C., & Ayres, J. G. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.141168 · Cited by 118
Relationship between cigarette smoking and Graves’ ophthalmopathy
Hegedűs, L. D., Brix, T. H., & Vestergaard, P. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345276 · Cited by 108
Efficacy and Safety of Orbital Radiotherapy for Graves' Orbitopathy
Tanda, M. L., & Bartalena, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2758 · Cited by 104
Self-citationPrevention of Graves’ ophthalmopathy
Bartalena, L. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.09.004 · Cited by 103
Self-citationPathogenesis of Graves’ orbitopathy: A 2010 update
Smith, T. J. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03346614 · Cited by 97
Psychological disturbance in graves ophthalmopathy.
Farid, M., Roch-Levecq, A.-C., Levi, L., Brody, B. L., Granet, D., & Kikkawa, D. (2005) · A M A Archives of Ophthalmology · doi:10.1001/archopht.123.4.491 · Cited by 95
The Dilemma of How to Manage Graves' Hyperthyroidism in Patients with Associated Orbitopathy
Bartalena, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2329 · Cited by 93
Self-citationPotential Utility of Rituximab for Graves' Orbitopathy
Salvi, M., Vannucchi, G. M., & Beck‐Peccoz, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1804 · Cited by 91
Surgical treatment of Graves’ ophthalmopathy
Eckstein, A. K., Schittkowski, M., & Esser, J. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.11.002 · Cited by 90
Al‐Daghri, N. M., Al-Attas, O. S., Alokail, M. S., Alkharfy, K. M., Al-Othman, A., Draz, H. M., Yakout, S. M., Al-Saleh, Y., Al-Yousef, M., Sabico, S., et al. (2013) · PubMed · doi:10.3275/8183 · Cited by 88
Turcu, A. F., Kumar, S., Neumann, S., Coenen, M., Iyer, S., Chiriboga, P., Gershengorn, M. C., & Bahn, R. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1149 · Cited by 84
Adalimumab as Steroid-Sparing Treatment of Inflammatory-Stage Thyroid Eye Disease
Ayabe, R. I., Rootman, D. B., Hwang, C. J., Ben‐Artzi, A., & Goldberg, R. A. (2014) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000211 · Cited by 83
Graves' Orbitopathy: Imperfect Treatments for a Rare Disease
Bartalena, L. (2013) · European Thyroid Journal · doi:10.1159/000356042 · Cited by 82
Self-citationStan, M. N., Durski, J. M., Brito, J. P., Bhagra, S., Thapa, P., & Bahn, R. S. (2013) · Thyroid · doi:10.1089/thy.2012.0258 · Cited by 77
van Steensel, L., Paridaens, D. A., Schrijver, B., Dingjan, G. M., van Daele, P. L. A., van Hagen, P. M., van den Bosch, W. A., Drexhage, H. A., Hooijkaas, H., & Dik, W. A. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2443 · Cited by 76
De Bellis, A., Conzo, G., Cennamo, G., Pane, E., Bellastella, G., Colella, C., Iacovo, A. D., Paglionico, V. A., Sinisi, A. A., Wall, J. R., et al. (2012) · Endocrine · doi:10.1007/s12020-011-9559-x · Cited by 69
Estcourt, S., Hickey, J., Perros, P., Dayan, C. M., & Vaidya, B. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0383 · Cited by 67
Leo, M., Marcocci, C., Pinchera, A., Nardi, M., Megna, L., Rocchi, R., Latrofa, F., Altea, M. A., Mazzi, B., Sisti, E., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2077 · Cited by 66
Zhao, P., Deng, Y., Gu, P., Wang, Y., Zhou, H., Hu, Y., Chen, P., & Fan, X. (2012) · Experimental Eye Research · doi:10.1016/j.exer.2012.11.014 · Cited by 65
Dose of intravenous steroids and therapy outcome in Graves’ orbitopathy
Zang, S., Ponto, K. A., Pitz, S., & Kahaly, G. J. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03346732 · Cited by 55
Moleti, M., Violi, M. A., Montanini, D., Trombetta, C. J., Bella, B. D., Sturniolo, G., Presti, S., Alibrandi, A., Campennì, A., Baldari, S., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3093 · Cited by 50
Rituximab for thyroid-associated ophthalmopathy
Minakaran, N., & Ezra, D. G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009226.pub2 · Cited by 49
Graves' Dermopathy and Acropachy Are Markers of Severe Graves' Ophthalmopathy
Fatourechi, V., Bartley, G. B., Eghbali-Fatourechi, G. Z., Powell, C. C., Ahmed, D. D. F., & Garrity, J. A. (2003) · Thyroid · doi:10.1089/10507250360731541 · Cited by 48
Self-citationTrauma and Pressure Explain the Clinical Presentation of the Graves' Disease Triad
Davies, T. F. (2000) · Thyroid · doi:10.1089/10507250050137680 · Cited by 36
What to do for moderate‐to‐severe and active Graves’ orbitopathy if glucocorticoids fail?
Bartalena, L. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03783.x · Cited by 33
Self-citationRole of oxidative stress and selenium in Graves' hyperthyroidism and orbitopathy.
Marcocci, C., & Bartalena, L. (2013) · PubMed · Cited by 32
Self-citationIs IGF-I Receptor a Target for Autoantibody Generation in Graves' Disease?
Smith, T. J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1004 · Cited by 32
Treatment‐resistant elephantiasic thyroid dermopathy responding to rituximab and plasmapheresis
Heyes, C., Nolan, R., Leahy, M. F., et al. (2010) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.2010.00693.x · Cited by 30
Treatment of Pretibial Myxedema with Dexamethazone Injected Subcutaneously by Mesotherapy Needles
Vannucchi, G. M., Campi, I., Covelli, D., Forzenigo, L. V., Beck‐Peccoz, P., & Salvi, M. (2013) · Thyroid · doi:10.1089/thy.2012.0429 · Cited by 27
Bartalena, L. (2014) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000221 · Cited by 19
Self-citation
Cited by
Global epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552
Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
Self-citationDe Leo, S., Lee, S. Y., & Braverman, L. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00278-6 · Cited by 883
Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases
Fröhlich, E., & Wahl, R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00521 · Cited by 455
Management of Graves Disease: A Review
Burch, H. B., & Cooper, D. S. (2015) · JAMA · doi:10.1001/jama.2015.16535 · Cited by 332
Metadata
- Authors
- Bartalena, L., & Fatourechi, V.
- Venue
- Journal of Endocrinological Investigation
- Published
- 2014-06-10
- Volume
- 37
- Issue
- 8
- Pages
- 691-700
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W2079726869
- Cited by
- 279
- References
- 69
- FWCI
- 19.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.